Novo exits $285M Ascendis deal for monthly GLP-1 obesity drug
The termination ends a collaboration aimed at developing a once-monthly GLP-1 therapy for obesity.
MH
By Maren Holt · Senior Reporter, GLP-1
Sep 15 05:19 ETSource: fiercebiotech.com
The wire
- 01Novo Nordisk walked away from a $285 million pact with Ascendis on a monthly GLP-1 obesity drug.
- 02Signals Novo narrowing external bets as it defends its obesity franchise.
- 03Reason for the exit and Ascendis' next steps remain unstated.
From the source
Read at news.google.comNovo walks away from $285M pact to develop monthly GLP-1 obesity drug with Ascendis